Resistance to Anti-VEGF Therapy in Cancer: Alternative Mechanisms
노바스템
2024-04-18
조회수 248
This article discusses the limitations of anti-VEGF therapies in cancer treatment, particularly focusing on why some patients exhibit resistance to these drugs. VEGF (Vascular Endothelial Growth Factor) pathway inhibitors, such as Bevacizumab, have been widely used to suppress tumor growth by hindering blood vessel formation. However, many patients develop resistance through mechanisms independent of the VEGF pathway. The review details alternative angiogenic pathways and cellular changes that contribute to this resistance. For example, upregulation of Angiopoietin-2 (Ang2) and activation of the FGF (Fibroblast Growth Factor) pathway can circumvent VEGF inhibition. The paper also highlights how cancer cells adapt to anti-angiogenic therapy by modifying their phenotype to enhance invasiveness and metastasis.
Just as cancer therapies struggle with drug resistance due to alternate angiogenic pathways, Novastem's stem cell therapies could be influenced by similar resistance mechanisms in regenerative medicine. Understanding these pathways in cancer can provide insights into managing resistance in stem cell therapies, particularly in conditions that involve tissue regeneration and repair where angiogenesis plays a crucial role.
Alternative Pathways: Beyond VEGF, factors like Ang2 and FGF contribute to angiogenesis and tumor survival, suggesting targets for multi-pathway therapy.
Cellular Adaptations: Cancer cells adapt to anti-VEGF therapy by becoming more invasive, indicating the need for treatments that can prevent these adaptations.
Implications for Stem Cell Therapy: The mechanisms of resistance in cancer therapy could inform strategies to improve the efficacy of stem cell-based treatments in regenerative medicine.
This article discusses the limitations of anti-VEGF therapies in cancer treatment, particularly focusing on why some patients exhibit resistance to these drugs. VEGF (Vascular Endothelial Growth Factor) pathway inhibitors, such as Bevacizumab, have been widely used to suppress tumor growth by hindering blood vessel formation. However, many patients develop resistance through mechanisms independent of the VEGF pathway. The review details alternative angiogenic pathways and cellular changes that contribute to this resistance. For example, upregulation of Angiopoietin-2 (Ang2) and activation of the FGF (Fibroblast Growth Factor) pathway can circumvent VEGF inhibition. The paper also highlights how cancer cells adapt to anti-angiogenic therapy by modifying their phenotype to enhance invasiveness and metastasis.
Just as cancer therapies struggle with drug resistance due to alternate angiogenic pathways, Novastem's stem cell therapies could be influenced by similar resistance mechanisms in regenerative medicine. Understanding these pathways in cancer can provide insights into managing resistance in stem cell therapies, particularly in conditions that involve tissue regeneration and repair where angiogenesis plays a crucial role.
#AntiVEGF #CancerResistance #Angiogenesis #StemCellTherapy #Novastem #Ang2 #FGFPathway #TumorAdaptation